When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
SGIOY - ViiV's fostemsavir shows long-term benefit in treatment-experienced HIV patients
Shionogi & Co. Ltd. ADR
Results from a Phase 3 clinical trial, BRIGHTE, evaluating ViiV Healthcare's fostemsavir in heavily pretreated HIV patients showed a treatment benefit. The data were presented at the International AIDS Society Conference on HIV Science in Mexico City.
More news on: GlaxoSmithKline plc, Pfizer Inc., Shionogi & Co., Ltd., Healthcare stocks news,